Charles Schwab
CTSO icon

Charles Schwab’s Cytosorbents Corp CTSO Stock Holding History

Charles Schwab’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,994
Closed -$17.8K – 3479
2023
Q4 		$17.8K Hold
15,994
– – ﹤0.01% 3494
2023
Q3 		$30.1K Sell
15,994
-500
-3% -$1.44K ﹤0.01% 3468
2023
Q2 		$59.2K Buy
16,494
+500
+3% +$1.58K ﹤0.01% 3399
2023
Q1 		$53.9K Hold
15,994
– – ﹤0.01% 3337
2022
Q4 		$24.8K Hold
15,994
– – ﹤0.01% 3476
2022
Q3 		$22K Hold
15,994
– – ﹤0.01% 3472
2022
Q2 		$36K Sell
15,994
-89,699
-85% -$206K ﹤0.01% 3437
2022
Q1 		$338K Buy
105,693
+562
+0.5% +$2.01K ﹤0.01% 3191
2021
Q4 		$441K Buy
105,131
+2,253
+2% +$12.6K ﹤0.01% 3185
2021
Q3 		$836K Sell
102,878
-518
-0.5% -$4.21K ﹤0.01% 2935
2021
Q2 		$781K Sell
103,396
-996
-1% -$8.39K ﹤0.01% 3016
2021
Q1 		$907K Buy
104,392
+3,113
+3% +$29.7K ﹤0.01% 2893
2020
Q4 		$808K Buy
101,279
+6,285
+7% +$52.6K ﹤0.01% 2836
2020
Q3 		$758K Buy
94,994
+10,914
+13% +$98.5K ﹤0.01% 2747
2020
Q2 		$833K Buy
84,080
+2,899
+4% +$26.6K ﹤0.01% 2681
2020
Q1 		$628K Hold
81,181
– – ﹤0.01% 2638
2019
Q4 		$313K Sell
81,181
-5,683
-7% -$24.8K ﹤0.01% 2963
2019
Q3 		$437K Buy
86,864
+5,594
+7% +$32.5K ﹤0.01% 2854
2019
Q2 		$538K Buy
81,270
+19,439
+31% +$134K ﹤0.01% 2776
2019
Q1 		$469K Sell
61,831
-1,322
-2% -$10.3K ﹤0.01% 2784
2018
Q4 		$511K Buy
63,153
+729
+1% +$7.24K ﹤0.01% 2761
2018
Q3 		$806K Buy
62,424
+2,627
+4% +$32.9K ﹤0.01% 2691
2018
Q2 		$682K Buy
+59,797
New +$566K ﹤0.01% 2696

Other funds holding CTSO

AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Charles Schwab's CTSO Position: Q1 2024 in Review

Charles Schwab sold out of Cytosorbents Corp (CTSO) in Q1 2024, closing a stake of 15,994 shares — an estimated $17.8K sold.

Charles Schwab first reported a position in CTSO in Q2 2018 and held it in 23 quarters. The position peaked at $907K in Q1 2021. 50 funds tracked by Wall St. Rank hold CTSO as of Q1 2024.

  • Charles Schwab reported no remaining Cytosorbents Corp position as of Q1 2024 after selling out during the quarter.
  • Charles Schwab sold 15,994 Cytosorbents Corp shares in Q1 2024, an estimated $17.8K.
  • Charles Schwab first reported a position in Cytosorbents Corp in Q2 2018 and held it in 23 quarters.
  • Charles Schwab's Cytosorbents Corp position peaked at $907K in Q1 2021.
  • 50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2024.

Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.